Two Sigma Advisers’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Two Sigma Advisers’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,070	Closed	-$37K	–	2718
2023 Q1	$37K	Hold	4,070	–	–	﹤0.01%	2478
2022 Q4	$47.8K	Sell	4,070 -2,747	-40%	-$48.5K	﹤0.01%	2369
2022 Q3	$144K	Sell	6,817 -6,010	-47%	-$162K	﹤0.01%	2261
2022 Q2	$311K	Sell	12,827 -2,566	-17%	-$87.3K	﹤0.01%	2110
2022 Q1	$767K	Buy	15,393 +4,946	+47%	+$244K	﹤0.01%	1779
2021 Q4	$733K	Buy	+10,447	New	+$880K	﹤0.01%	1725
2021 Q1	–	Sell	-750	Closed	-$62K	–	2763
2020 Q4	$62K	Sell	750 -15,417	-95%	-$1.31M	﹤0.01%	2305
2020 Q3	$1.39M	Buy	16,167 +8,174	+102%	+$952K	﹤0.01%	1352
2020 Q2	$743K	Buy	+7,993	New	+$440K	﹤0.01%	1717
2020 Q1	–	Sell	-830	Closed	-$34K	–	2594
2019 Q4	$34K	Buy	+830	New	+$18.2K	﹤0.01%	2303

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Advisers's VBIV Position: Q2 2023 in Review

Two Sigma Advisers sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 4,070 shares — an estimated $37K sold.

Two Sigma Advisers first reported a position in VBIV in Q4 2019 and held it in 10 quarters. The position peaked at $1.39M in Q3 2020. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

Two Sigma Advisers reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
Two Sigma Advisers sold 4,070 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $37K.
Two Sigma Advisers first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2019 and held it in 10 quarters.
Two Sigma Advisers's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $1.39M in Q3 2020.
46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.